297 related articles for article (PubMed ID: 28154176)
41. PPDPF Promotes the Development of Mutant KRAS-Driven Pancreatic Ductal Adenocarcinoma by Regulating the GEF Activity of SOS1.
Ni QZ; Zhu B; Ji Y; Zheng QW; Liang X; Ma N; Jiang H; Zhang FK; Shang YR; Wang YK; Xu S; Zhang EB; Yuan YM; Chen TW; Yin FF; Cao HJ; Huang JY; Xia J; Ding XF; Qiu XS; Ding K; Song C; Zhou WT; Wu M; Wang K; Lui R; Lin Q; Chen W; Li ZG; Cheng SQ; Wang XF; Xie D; Li JJ
Adv Sci (Weinh); 2023 Jan; 10(2):e2202448. PubMed ID: 36453576
[TBL] [Abstract][Full Text] [Related]
42. Molecular dynamics simulations of Gly-12-->Val mutant of p21(ras): dynamic inhibition mechanism.
Futatsugi N; Tsuda M
Biophys J; 2001 Dec; 81(6):3483-8. PubMed ID: 11721009
[TBL] [Abstract][Full Text] [Related]
43. Synaptic GAP and GEF Complexes Cluster Proteins Essential for GTP Signaling.
Wilkinson B; Li J; Coba MP
Sci Rep; 2017 Jul; 7(1):5272. PubMed ID: 28706196
[TBL] [Abstract][Full Text] [Related]
44. Structures of RGL1 RAS-Association Domain in Complex with KRAS and the Oncogenic G12V Mutant.
Eves BJ; Gebregiworgis T; Gasmi-Seabrook GMC; Kuntz DA; Privé GG; Marshall CB; Ikura M
J Mol Biol; 2022 May; 434(9):167527. PubMed ID: 35257782
[TBL] [Abstract][Full Text] [Related]
45. Regulators and effectors of ras proteins.
Bollag G; McCormick F
Annu Rev Cell Biol; 1991; 7():601-32. PubMed ID: 1667084
[No Abstract] [Full Text] [Related]
46. Identification of amino acid residues of Ras protein that are essential for signal-transducing activity but not for enhancement of GTPase activity by GAP.
Fujita-Yoshigaki J; Shirouzu M; Koide H; Nishimura S; Yokoyama S
FEBS Lett; 1991 Dec; 294(3):187-90. PubMed ID: 1756860
[TBL] [Abstract][Full Text] [Related]
47. NMR Detection Methods for Profiling RAS Nucleotide Cycling.
Killoran RC; Smith MJ
Methods Mol Biol; 2021; 2262():169-182. PubMed ID: 33977476
[TBL] [Abstract][Full Text] [Related]
48. A synthetic peptide corresponding to a sequence in the GTPase activating protein inhibits p21ras stimulation and promotes guanine nucleotide exchange.
Rubinfeld B; Wong G; Bekesi E; Wood A; Heimer E; McCormick F; Polakis P
Int J Pept Protein Res; 1991 Jul; 38(1):47-53. PubMed ID: 1938104
[TBL] [Abstract][Full Text] [Related]
49. X-ray crystal structures of transforming p21 ras mutants suggest a transition-state stabilization mechanism for GTP hydrolysis.
Privé GG; Milburn MV; Tong L; de Vos AM; Yamaizumi Z; Nishimura S; Kim SH
Proc Natl Acad Sci U S A; 1992 Apr; 89(8):3649-53. PubMed ID: 1565661
[TBL] [Abstract][Full Text] [Related]
50. Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy.
Xu K; Park D; Magis AT; Zhang J; Zhou W; Sica GL; Ramalingam SS; Curran WJ; Deng X
Mol Cancer; 2019 Apr; 18(1):85. PubMed ID: 30971271
[TBL] [Abstract][Full Text] [Related]
51. Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants.
Alcantara KMM; Malapit JRP; Yu RTD; Garrido JAMG; Rigor JPT; Angeles AKJ; Cutiongco-de la Paz EM; Garcia RL
Cells; 2019 Dec; 8(12):. PubMed ID: 31816869
[TBL] [Abstract][Full Text] [Related]
52. Characterisation of the nucleotide exchange factor ITSN1L: evidence for a kinetic discrimination of GEF-stimulated nucleotide release from Cdc42.
Kintscher C; Groemping Y
J Mol Biol; 2009 Mar; 387(2):270-83. PubMed ID: 19356586
[TBL] [Abstract][Full Text] [Related]
53. Real-Time Monitoring of RAS Activity Using In Vitro and In-Cell NMR Spectroscopy.
Zhao Q; Shimada I; Nishida N
Methods Mol Biol; 2024; 2797():237-252. PubMed ID: 38570464
[TBL] [Abstract][Full Text] [Related]
54. Role of glutamine-61 in the hydrolysis of GTP by p21H-ras: an experimental and theoretical study.
Frech M; Darden TA; Pedersen LG; Foley CK; Charifson PS; Anderson MW; Wittinghofer A
Biochemistry; 1994 Mar; 33(11):3237-44. PubMed ID: 8136358
[TBL] [Abstract][Full Text] [Related]
55. GTP-Bound N-Ras Conformational States and Substates Are Modulated by Membrane and Point Mutation.
Farcas A; Janosi L
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338709
[TBL] [Abstract][Full Text] [Related]
56. KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis.
Rabara D; Tran TH; Dharmaiah S; Stephens RM; McCormick F; Simanshu DK; Holderfield M
Proc Natl Acad Sci U S A; 2019 Oct; 116(44):22122-22131. PubMed ID: 31611389
[No Abstract] [Full Text] [Related]
57. Isoform-Specific Destabilization of the Active Site Reveals a Molecular Mechanism of Intrinsic Activation of KRas G13D.
Johnson CW; Lin YJ; Reid D; Parker J; Pavlopoulos S; Dischinger P; Graveel C; Aguirre AJ; Steensma M; Haigis KM; Mattos C
Cell Rep; 2019 Aug; 28(6):1538-1550.e7. PubMed ID: 31390567
[TBL] [Abstract][Full Text] [Related]
58. Regulation of small GTPases by GEFs, GAPs, and GDIs.
Cherfils J; Zeghouf M
Physiol Rev; 2013 Jan; 93(1):269-309. PubMed ID: 23303910
[TBL] [Abstract][Full Text] [Related]
59. Regulation of RAS oncogenicity by acetylation.
Yang MH; Nickerson S; Kim ET; Liot C; Laurent G; Spang R; Philips MR; Shan Y; Shaw DE; Bar-Sagi D; Haigis MC; Haigis KM
Proc Natl Acad Sci U S A; 2012 Jul; 109(27):10843-8. PubMed ID: 22711838
[TBL] [Abstract][Full Text] [Related]
60. Three-dimensional structures and properties of a transforming and a nontransforming glycine-12 mutant of p21H-ras.
Franken SM; Scheidig AJ; Krengel U; Rensland H; Lautwein A; Geyer M; Scheffzek K; Goody RS; Kalbitzer HR; Pai EF
Biochemistry; 1993 Aug; 32(33):8411-20. PubMed ID: 8357792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
